{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:37Z","timestamp":1791874717345,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005343","name":"Fundaci\u00f3n IMSS","doi-asserted-by":"publisher","award":["R-2019-785-052"],"award-info":[{"award-number":["R-2019-785-052"]}],"id":[{"id":"10.13039\/501100005343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pituitary neuroendocrine tumors (PitNET) represent the vast majority of sellar masses. Some behave aggressively, growing rapidly and invading surrounding tissues, with high rates of recurrence and resistance to therapy. Our aim was to establish patterns of genomic, transcriptomic and methylomic evolution throughout time in primary and recurrent tumors from the same patient. Therefore, we performed transcriptome- and exome-sequencing and methylome microarrays of aggressive, primary, and recurrent PitNET from the same patient. Primary and recurrent tumors showed a similar exome profile, potentially indicating a stable genome over time. In contrast, the transcriptome of primary and recurrent PitNET was dissimilar. Gonadotroph, silent corticotroph, as well as metastatic corticotroph and a somatotroph PitNET expressed genes related to fatty acid biosynthesis and metabolism, phosphatidylinositol signaling, glycerophospholipid and phospholipase D signaling, respectively<jats:bold>.<\/jats:bold> Diacylglycerol kinase gamma (DGKG), a key enzyme in glycerophospholipid metabolism and phosphatidylinositol signaling pathways, was differentially expressed between primary and recurrent PitNET. These alterations did not seem to be regulated by DNA methylation, but rather by several transcription factors. Molecular docking showed that dasatinib, a small molecule tyrosine kinase inhibitor used in the treatment of chronic lymphocytic and acute lymphoblastic leukemia, could target DGKG. Dasatinib induced apoptosis and decreased proliferation in GH3 cells. Our data indicate that pituitary tumorigenesis could be driven by transcriptomically heterogeneous clones, and we describe alternative pharmacological therapies for aggressive and recurrent PitNET.<\/jats:p>","DOI":"10.1186\/s40478-024-01796-x","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T09:02:18Z","timestamp":1725094938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways"],"prefix":"10.1186","volume":"12","author":[{"given":"Keiko","family":"Taniguchi-Ponciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Hinojosa-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Hernandez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio A.","family":"Chavez-Santoscoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Remba-Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Guinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Magallon-Gayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Telles-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Ponce","family":"de Leon-Conconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vela-Pati\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Andonegui-Elguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amayrani","family":"Cano-Zaragoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Martinez-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Kerbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Loza-Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rodrigo-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Mendez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Aguilar-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonieta","family":"Chavez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elenka","family":"Ortiz-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Gomez-Apo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Bonifaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-6654","authenticated-orcid":false,"given":"Daniel","family":"Marrero-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"issue":"10","key":"1796_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382(10):937\u2013950","journal-title":"N Engl J Med"},{"issue":"5","key":"1796_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"M Molitch","year":"2017","unstructured":"Molitch M (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5):516\u2013524","journal-title":"JAMA"},{"issue":"2","key":"1796_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10014-017-0307-7","volume":"35","author":"H Nishioka","year":"2018","unstructured":"Nishioka H, Inoshita N (2018) New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol 35(2):57\u201361","journal-title":"Brain Tumor Pathol"},{"issue":"11","key":"1796_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T (2021) Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17(11):671\u2013684","journal-title":"Nat Rev Endocrinol"},{"key":"1796_CR5","doi-asserted-by":"publisher","first-page":"748997","DOI":"10.3389\/fendo.2021.748997","volume":"12","author":"W Chen","year":"2021","unstructured":"Chen W, Wang M, Duan C, Yao S, Jiao H, Wang Z et al (2021) Prediction of the recurrence of non-functioning pituitary adenomas using preoperative supra-intra sellar volume and tumor-carotid distance. Front Endocrinol (Lausanne) 12:748997","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1796_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-10-0255","volume":"163","author":"S Brochier","year":"2010","unstructured":"Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C et al (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163(2):193\u2013200","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1796_CR7","doi-asserted-by":"publisher","first-page":"19373","DOI":"10.1038\/s41598-020-76555-8","volume":"10","author":"K Taniguchi-Ponciano","year":"2020","unstructured":"Taniguchi-Ponciano K, Andonegui-Elguera S, Pe\u00f1a-Mart\u00ednez E-R, G, Vela-Pati\u00f1o S, Gomez-Apo E, et al (2020) Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Sci Rep 10(1):19373","journal-title":"Sci Rep"},{"issue":"7","key":"1796_CR8","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/mc.22631","volume":"56","author":"M Kai","year":"2017","unstructured":"Kai M, Yamamoto E, Sato A, Tamano HO, Niinuma T, Kitajima H et al (2017) Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer. Mol Carcinog 56(7):1743\u20131752","journal-title":"Mol Carcinog"},{"issue":"15","key":"1796_CR9","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan A, Soleimani M, Mandal SS (2017) Long noncoding RNA and cancer: a new paradigm. Cancer Res 77(15):3965\u20133981","journal-title":"Cancer Res"},{"issue":"43","key":"1796_CR10","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1038\/s41388-020-01459-w","volume":"39","author":"Y Chen","year":"2020","unstructured":"Chen Y, Xu L, Lin RY, M\u00fcschen M, Koeffler HP (2020) Core transcriptional regulatory circuitries in cancer. Oncogene 39(43):6633\u20136646","journal-title":"Oncogene"},{"issue":"9","key":"1796_CR11","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.3390\/ijms23094861","volume":"23","author":"S Andonegui-Elguera","year":"2022","unstructured":"Andonegui-Elguera S, Silva-Rom\u00e1n G, Pe\u00f1a-Mart\u00ednez E, Taniguchi-Ponciano K, Vela-Pati\u00f1o S, Remba-Shapiro I et al (2022) The genomic landscape of corticotroph tumors: from silent adenomas to ACTH-secreting carcinomas. Int J Mol Sci 23(9):4861","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1796_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M (2021) Navigating the DNA methylation landscape of cancer. Trends Genet 37(11):1012\u20131027","journal-title":"Trends Genet"},{"issue":"1","key":"1796_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12920-022-01206-y","volume":"15","author":"K Taniguchi-Ponciano","year":"2022","unstructured":"Taniguchi-Ponciano K, Portocarrero-Ortiz LA, Guinto G, Moreno-Jimenez S, Gomez-Apo E, Chavez-Macias L et al (2022) The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages. BMC Med Genomics 15(1):52","journal-title":"BMC Med Genomics"},{"issue":"10","key":"1796_CR14","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.bjc.6605381","volume":"101","author":"GE Konecny","year":"2009","unstructured":"Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR et al (2009) Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 101(10):1699\u20131708","journal-title":"Br J Cancer"},{"key":"1796_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/DDDT.S124102","volume":"11","author":"A Kadivar","year":"2017","unstructured":"Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R, Noordin MI (2017) Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-\u03b2, PDGF-BB, c-Kit and SCF genes. Drug Des Devel Ther 11:469\u2013481","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"1796_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrendo.2011.40","volume":"7","author":"S Melmed","year":"2011","unstructured":"Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7(5):257\u2013266","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1796_CR17","doi-asserted-by":"publisher","first-page":"100934","DOI":"10.1016\/j.xcrm.2023.100934","volume":"4","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Yao B, Long X, Chen Z, He M, Wu Y et al (2023) Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET. Cell Rep Med 4(2):100934","journal-title":"Cell Rep Med"},{"issue":"12","key":"1796_CR18","doi-asserted-by":"publisher","first-page":"e0168984","DOI":"10.1371\/journal.pone.0168984","volume":"11","author":"A Sundstrom","year":"2016","unstructured":"Sundstrom A, Bar-Sagi D, Mishra B (2016) Simulating heterogeneous tumor cell populations. PLoS ONE 11(12):e0168984","journal-title":"PLoS ONE"},{"key":"1796_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.copbio.2014.07.004","volume":"21","author":"S Di Palma","year":"2015","unstructured":"Di Palma S, Bodenmiller B (2015) Unraveling cell populations in tumors by single-cell mass cytometry. Curr Opin Biotechnol 21:122\u2013129","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"1796_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13062-016-0143-4","volume":"11","author":"T Lorenzi","year":"2016","unstructured":"Lorenzi T, Chisholm R, Clairambault J (2016) Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations. Biol Direct 11(1):43","journal-title":"Biol Direct"},{"issue":"1","key":"1796_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13073-021-01000-y","volume":"13","author":"C Suphavilai","year":"2021","unstructured":"Suphavilai C, Chia S, Sharma A, Tu L, Da Silva RP, Mongia A et al (2021) Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures. Genome Med 13(1):189","journal-title":"Genome Med"},{"issue":"11","key":"1796_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"J Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso J (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7(11):834\u2013846","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1796_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-21-2244","volume":"28","author":"P Weber","year":"2022","unstructured":"Weber P, K\u00fcnstner A, Hess J, Unger K, Marschner S, Idel C et al (2022) Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer. Clin Cancer Res 28(5):1038\u20131052","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1796_CR24","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1053\/j.gastro.2019.09.005","volume":"157","author":"X Ding","year":"2019","unstructured":"Ding X, He M, Chan AWH, Song QX, Sze SC, Chen H et al (2019) Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 157(6):1630\u20131645","journal-title":"Gastroenterology"},{"issue":"6","key":"1796_CR25","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1172\/JCI89914","volume":"127","author":"KM Havas","year":"2017","unstructured":"Havas KM, Milchevskaya V, Radic K, Alladin A, Kafkia E, Garcia M et al (2017) Metabolic shifts in residual breast cancer drive tumor recurrence. J Clin Invest 127(6):2091\u20132105","journal-title":"J Clin Invest"},{"issue":"1","key":"1796_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41389-022-00420-8","volume":"11","author":"S Vasseur","year":"2022","unstructured":"Vasseur S, Guillaumond F (2022) Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance. Oncogenesis 11(1):46","journal-title":"Oncogenesis"},{"issue":"1","key":"1796_CR27","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1038\/s41467-020-17512-x","volume":"11","author":"W Zhou","year":"2020","unstructured":"Zhou W, Yao Y, Scott AJ, Wilder-Romans K, Dresser JJ, Werner CK et al (2020) Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun 11(1):3811","journal-title":"Nat Commun"},{"key":"1796_CR28","doi-asserted-by":"publisher","first-page":"583053","DOI":"10.3389\/fonc.2020.583053","volume":"10","author":"WJ Su","year":"2021","unstructured":"Su WJ, Lu PZ, Wu Y, Kalpana K, Yang CK, Lu GD (2021) Identification of key genes in purine metabolism as prognostic biomarker for hepatocellular carcinoma. Front Oncol 10:583053","journal-title":"Front Oncol"},{"issue":"1","key":"1796_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13048-022-01022-z","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Hong S, Yang J, Zhang X, Wang Y, Wang H et al (2022) Targeting purine metabolism in ovarian cancer. J Ovarian Res 15(1):93","journal-title":"J Ovarian Res"},{"issue":"19","key":"1796_CR30","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.3390\/cancers14194568","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li Q, Huang Z, Li B, Nice EC, Huang C et al (2022) Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers (Basel) 14(19):4568","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1796_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller JH (2019) Targeting transcription factors in cancer-from undruggable to reality. Nat Rev Cancer 19(11):611\u2013624","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1796_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1755-8794-3-13","volume":"28","author":"X Zhan","year":"2010","unstructured":"Zhan X, Desiderio DM (2010) Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genom 28(3):13","journal-title":"BMC Med Genom"},{"issue":"1","key":"1796_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s12276-020-00551-1","volume":"53","author":"D Lv","year":"2021","unstructured":"Lv D, Zhou L, Tang H (2021) Hepatocyte nuclear factor 4\u03b1 and cancer-related cell signaling pathways: a promising insight into cancer treatment. Exp Mol Med 53(1):8\u201318","journal-title":"Exp Mol Med"},{"issue":"7","key":"1796_CR34","doi-asserted-by":"publisher","first-page":"e004825","DOI":"10.1136\/jitc-2022-004825","volume":"10","author":"JD Park","year":"2022","unstructured":"Park JD, Kim KS, Choi SH, Jo GH, Choi JH, Park SW, Ko ES, Lee M, Lee DK, Jang HJ, Hwang S, Jung HY, Park KS (2022) ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics. J Immunother Cancer 10(7):e004825","journal-title":"J Immunother Cancer"},{"key":"1796_CR35","doi-asserted-by":"publisher","first-page":"608748","DOI":"10.3389\/fonc.2021.608748","volume":"11","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ren Z, Zhang C, Qian R, Wang H, Wang J et al (2021) ELK3: a new molecular marker for the diagnosis and prognosis of glioma. Front Oncol 11:608748","journal-title":"Front Oncol"},{"key":"1796_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2891-13-17","volume":"13","author":"B Grygiel-G\u00f3rniak","year":"2014","unstructured":"Grygiel-G\u00f3rniak B (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications\u2013a review. Nutr J 13:17","journal-title":"Nutr J"},{"issue":"1","key":"1796_CR37","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s41467-019-09152-7","volume":"10","author":"R Bertolio","year":"2019","unstructured":"Bertolio R, Napoletano F, Mano M, Maurer-Stroh S, Fantuz M, Zannini A (2019) Sterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism. Nat Commun 10(1):1326","journal-title":"Nat Commun"},{"key":"1796_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1741-7015-7-68","volume":"7","author":"SP Pitroda","year":"2009","unstructured":"Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, MacDermed DM et al (2009) STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med 7:68","journal-title":"BMC Med"},{"issue":"9","key":"1796_CR39","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1172\/JCI200316575","volume":"111","author":"AP Heaney","year":"2003","unstructured":"Heaney AP, Fernando M, Melmed S (2003) PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111(9):1381\u20131388","journal-title":"J Clin Invest"},{"key":"1796_CR40","doi-asserted-by":"publisher","first-page":"624112","DOI":"10.3389\/fendo.2021.624112","volume":"12","author":"M Hernandez-Quiles","year":"2021","unstructured":"Hernandez-Quiles M, Broekema M, Kalkhoven E (2021) PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Front Endocrinol (Lausanne) 12:624112","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1796_CR41","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1038\/s41467-021-24656-x","volume":"12","author":"LY Li","year":"2021","unstructured":"Li LY, Yang Q, Jiang YY, Yang W, Jiang Y, Li X et al (2021) Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer. Nat Commun 12(1):4362","journal-title":"Nat Commun"},{"issue":"3","key":"1796_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tem.2016.01.001","volume":"27","author":"C Piperi","year":"2016","unstructured":"Piperi C, Adamopoulos C, Papavassiliou A (2016) XBP1: a pivotal transcriptional regulator of glucose and lipid metabolism. Trends Endocrinol Metab 27(3):119\u2013122","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"1796_CR43","doi-asserted-by":"publisher","first-page":"100802","DOI":"10.1016\/j.xcrm.2022.100802","volume":"3","author":"MPG Dings","year":"2022","unstructured":"Dings MPG, van der Zalm AP, Bootsma S, van Maanen TFJ, Waasdorp C et al (2022) Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. Cell Rep Med 3(11):100802","journal-title":"Cell Rep Med"},{"issue":"47","key":"1796_CR44","doi-asserted-by":"publisher","first-page":"24538","DOI":"10.1074\/jbc.M116.746370","volume":"291","author":"A Pozner","year":"2016","unstructured":"Pozner A, Terooatea T, Buck K (2016) B. ell-specific Kaiso (ZBTB33) regulation of cell cycle through cyclin D1 and cyclin E1. J Biol Chem. 291(47):24538\u201324550","journal-title":"J Biol Chem."},{"key":"1796_CR45","doi-asserted-by":"publisher","first-page":"110069","DOI":"10.1016\/j.biopha.2020.110069","volume":"127","author":"S Chen","year":"2020","unstructured":"Chen S, Chen J, Hua X, Sun Y, Cui R, Sha J, Zhu X (2020) The emerging role of XBP1 in cancer. Biomed Pharmacother 127:110069","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"1796_CR46","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41417-022-00487-w","volume":"29","author":"N Sideris","year":"2022","unstructured":"Sideris N, Dama P, Bayraktar S, Stiff T, Castellano L (2022) LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther 29(12):1866\u20131877","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"1796_CR47","doi-asserted-by":"publisher","first-page":"612393","DOI":"10.3389\/fmed.2020.612393","volume":"30","author":"Y Qian","year":"2020","unstructured":"Qian Y, Shi L, Luo Z (2020) Long non-coding RNAs in cancer: implications for diagnosis, prognosis, and therapy. Front Med (Lausanne) 30(7):612393","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"1796_CR48","first-page":"2538","volume":"12","author":"Z Liu","year":"2020","unstructured":"Liu Z, Han L, Yu H, Gao N, Xin H (2020) LINC01619 promotes non-small cell lung cancer development via regulating PAX6 by suppressing microRNA-129-5p. Am J Transl Res 12(6):2538\u20132553","journal-title":"Am J Transl Res"},{"key":"1796_CR49","doi-asserted-by":"publisher","first-page":"144604","DOI":"10.1016\/j.gene.2020.144604","volume":"743","author":"Z Miao","year":"2020","unstructured":"Miao Z, Liu S, Xiao X, Li D (2020) LINC00342 regulates cell proliferation, apoptosis, migration and invasion in colon adenocarcinoma via miR-545-5p\/MDM2 axis. Gene 743:144604","journal-title":"Gene"},{"issue":"24","key":"1796_CR50","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.omtn.2021.04.019","volume":"1","author":"DD Zhang","year":"2021","unstructured":"Zhang DD, Shi Y, Liu JB, Yang XL, Xin R, Wang HM, Wang PY, Jia CY, Zhang WJ, Ma YS, Fu D (2021) Construction of a Myc-associated ceRNA network reveals a prognostic signature in hepatocellular carcinoma. Mol Ther Nucleic Acids 1(24):1033\u20131050","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"1796_CR51","first-page":"4474","volume":"17","author":"Z Hu","year":"2019","unstructured":"Hu Z, Yang D, Tang Y, Zhang X, Wei Z, Fu H et al (2019) Five-long non-coding RNA risk score system for the effective prediction of gastric cancer patient survival. Oncol Lett 17(5):4474\u20134486","journal-title":"Oncol Lett"},{"issue":"22","key":"1796_CR52","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/1078-0432.CCR-15-0413","volume":"21","author":"B Purow","year":"2015","unstructured":"Purow B (2015) Molecular pathways: targeting diacylglycerol kinase alpha in cancer. Clin Cancer Res 21(22):5008\u20135012","journal-title":"Clin Cancer Res"},{"key":"1796_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fimmu.2013.00178","volume":"4","author":"S Krishna","year":"2013","unstructured":"Krishna S, Zhong X (2013) Regulation of lipid signaling by diacylglycerol kinases during T cell development and function. Front Immunol 4:178","journal-title":"Front Immunol"},{"issue":"20","key":"1796_CR54","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.3390\/cancers13205190","volume":"13","author":"F Sakane","year":"2021","unstructured":"Sakane F, Hoshino F, Ebina M, Sakai H, Takahashi D (2021) The roles of diacylglycerol kinase \u03b1 in cancer cell proliferation and apoptosis. Cancers (Basel) 13(20):5190","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1796_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12944-020-01286-8","volume":"19","author":"K Kolczynska","year":"2020","unstructured":"Kolczynska K, Loza-Valdes A, Hawro I, Sumara G (2020) Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review. Lipids Health Dis 19(1):113","journal-title":"Lipids Health Dis"},{"issue":"13","key":"1796_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/1471-2407-13-267","volume":"30","author":"AY Chang","year":"2013","unstructured":"Chang AY, Wang M (2013) Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer 30(13):267","journal-title":"BMC Cancer"},{"issue":"2","key":"1796_CR57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2141.2010.08507.x","volume":"153","author":"A McCaig","year":"2011","unstructured":"McCaig A, Cosimo E, Leach M, Michie A (2011) Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 153(2):199\u2013211","journal-title":"Br J Haematol"},{"key":"1796_CR58","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","volume":"1","author":"FM Johnson","year":"2005","unstructured":"Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 1:6924\u201332","journal-title":"Clin Cancer Res."},{"key":"1796_CR59","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fendo.2018.00453","volume":"9","author":"P Gupta","year":"2018","unstructured":"Gupta P, Rai A, Mukherjee KK, Sachdeva N, Radotra BD, Punia RPS et al (2018) Imatinib inhibits GH secretion from somatotropinomas. Front Endocrinol (Lausanne) 9:453","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1796_CR60","doi-asserted-by":"publisher","first-page":"e94554","DOI":"10.1371\/journal.pone.0094554","volume":"9","author":"DL Bodian","year":"2014","unstructured":"Bodian DL, McCutcheon JN, Kothiyal P, Huddleston KC, Iyer RK, Vockley JG et al (2014) Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. PLoS ONE 9(4):e94554","journal-title":"PLoS ONE"},{"issue":"4","key":"1796_CR61","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","volume":"106","author":"O Casar-Borota","year":"2021","unstructured":"Casar-Borota O, Boldt HB, Engstr\u00f6m BE, Andersen MS, Baussart B, Bengtsson D et al (2021) Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab. 106(4):1183\u20131194","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"1796_CR62","doi-asserted-by":"publisher","first-page":"e13169","DOI":"10.1111\/jne.13169","volume":"34","author":"H Lasolle","year":"2022","unstructured":"Lasolle H, Vasiljevic A, Jouanneau E, Ilie MD, Raverot G (2022) Aggressive corticotroph tumors and carcinomas. J Neuroendocrinol 34(8):e13169","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"1796_CR63","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1089\/gtmb.2014.0333","volume":"19","author":"S Yarman","year":"2015","unstructured":"Yarman S, Ogret YD, Oguz FS (2015) Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas? Genet Test Mol Biomarkers 19(7):394\u2013398","journal-title":"Genet Test Mol Biomarkers"},{"key":"1796_CR64","unstructured":"Hern\u00e1ndez-Ram\u00edrez LC, Gabrovska P, D\u00e9nes J, Stals K, Trivellin G, Tilley D, et al. (2015) International FIPA Consortium. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab. 100(9):E1242\u201354."}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-024-01796-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:10:42Z","timestamp":1725369042000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-024-01796-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1186\/s40478-024-01796-x","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Comisi\u00f3n Nacional de \u00c9tica e Investigaci\u00f3n Cient\u00edfica del Instituto Mexicano del Seguro Social (approval: R-2022-3601-186 and R-2019-785-052) and it has been caried out in accordance with the principles of the Helsinki declaration. All participating patients signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare not having any conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}